Эконазола нитрат

Quick links

Choose a section

Quick links to important sections

Advertisements

Эконазола нитрат

Advertisements
Advertisements

Treatment option: Balanitis, Vaginitis, Empeines

Advertisements

Overview of Эконазола нитрат

What is Econazole Nitrate?

Econazole nitrate is a synthetic broad-spectrum antifungal agent belonging to the imidazole class of medications. It is primarily utilized in dermatology to address various fungal and yeast infections of the skin. By inhibiting the growth of pathogenic fungi, it helps manage the clinical symptoms associated with these conditions.

Mechanism of Action

The therapeutic effect of econazole nitrate is rooted in its ability to disrupt the cellular integrity of fungi. It works by interfering with the synthesis of ergosterol, a vital component of the fungal cell membrane. When ergosterol production is inhibited, the cell membrane becomes permeable and loses its structural stability. This disruption leads to the leakage of essential cellular contents, ultimately resulting in the death of the fungal organism.

Spectrum of Activity

Econazole nitrate is effective against a wide range of microorganisms, including:

  • Dermatophytes: Fungi such as Trichophyton, Microsporum, and Epidermophyton that commonly cause conditions like ringworm and athlete's foot.
  • Yeasts: Particularly species of Candida, which are responsible for cutaneous candidiasis.
  • Molds: Various opportunistic fungi that can colonize the skin.
  • Gram-positive Bacteria: It also exhibits some antibacterial activity against certain bacteria that often complicate fungal skin infections.

Common Applications

As a versatile antifungal agent, econazole nitrate is commonly integrated into topical formulations to treat several specific skin conditions. These include:

  • Tinea Pedis (Athlete's Foot): Fungal infections affecting the feet and the spaces between the toes.
  • Tinea Cruris (Jock Itch): Fungal infections located in the groin or inner thigh areas.
  • Tinea Corporis (Ringworm): Fungal infections occurring on the trunk, legs, or arms.
  • Pityriasis Versicolor: A common condition characterized by small, discolored patches of skin caused by an overgrowth of yeast.
  • Cutaneous Candidiasis: Skin infections caused by Candida yeast, often appearing in skin folds or moist areas.
Advertisements

What side effects are possible with Эконазола нитрат?

Possible Side Effects and Safety Information

The safety profile for Econazole Nitrate is established by regulatory documentation, which classifies possible side effects based on system-organ class and reported frequency. Since the medicine is for topical use, the majority of documented adverse reactions relate to the area of application.

Officially Documented Adverse Reactions by Frequency

Classification Side Effect Examples
Common (Reported in 1/100 to < 1/10) Pruritus (itching), skin burning sensation
Uncommon (Reported in 1/1,000 to < 1/100) Rash, erythema (redness)
Frequency Not Known (Post-marketing) Hypersensitivity, Angioedema, Urticaria, contact dermatitis, application site pain/irritation/swelling

Serious adverse reactions are primarily related to Immune System Disorders. The documented presence of Hypersensitivity and related symptoms such as Angioedema and Urticaria defines the potential for rare, serious allergic events.

Population-Specific Safety and Restrictions

Official labeling includes safety statements for specific populations. For use during Pregnancy, animal studies showed fetotoxic or embryotoxic effects at high oral doses; the drug is therefore used only when potential benefits justify the risk. It is not known if the medication is excreted in human milk during Lactation.

A significant safety constraint involves drug interactions: the label notes a risk when Эконазола нитрат is used concurrently with the anticoagulant warfarin. If applied to large areas or under occlusion, specific monitoring of the International Normalized Ratio (INR) may be indicated to manage the risk of systemic consequence. The product is contraindicated in individuals with known hypersensitivity to any of its components.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is based on official government regulatory documents (e.g., FDA, EMA) regarding the overdose of topical Econazole Nitrate.


Documented Overdose Risk

Official regulatory information states that overdosage in humans has not been reported to date following the use of topical Econazole Nitrate formulations. Because of this, there are no specific, documented clinical manifestations (signs or symptoms) of overdose available from human case reports for this route of administration.

Regulatory Instructions and Emergency Action

Regulatory labeling emphasizes the appropriate use of this medication to prevent accidental overdose or misuse. The product is strictly for topical use only.

Primary Regulatory Instruction Implied Risk Mitigation
Do not use orally, intravaginally, or opthalmically. Misuse via unapproved routes may lead to systemic exposure and potential toxicity.
For topical use only. Reduces the risk of accidental ingestion or mucosal absorption.

When to Seek Urgent Medical Attention:

Although human overdose is rare with proper use, urgent medical attention should be sought immediately if accidental oral ingestion of the medication occurs, or if symptoms develop after the product has been used via an unapproved route.

Antidote and Management

No specific antidote for Econazole Nitrate overdose is listed in official labeling. Management of accidental ingestion would involve standard supportive measures and treatment of symptoms, as determined by a healthcare professional.

Advertisements

Therapeutic Uses of Эконазола нитрат

What Эконазола нитрат Treats: Main Uses and Benefits

The use of Эконазола нитрат is generally associated with managing fungal infections that affect the skin and mucous membranes. The medication is commonly used to help manage a range of superficial mycoses, providing supportive therapeutic benefit across several key symptomatic domains.

This medication is commonly used across conditions presenting with acute episodes of fungal or yeast growth, focusing on infections such as ringworm (tinea corporis), jock itch (tinea cruris), athlete's foot (tinea pedis), and is also relevant for managing cutaneous candidiasis and the discoloration of tinea versicolor.

The therapeutic focus is relevant for conditions presenting with symptomatic discomfort, which generally contributes to easing the overall symptom load and helps improve the potential for resolution of the infection. Эконазола нитрат is applied in addressing pronounced sensory symptoms like intense itching and the associated localized burning or stinging. This provides supportive relief that helps patients cope more steadily during periods of heightened discomfort, assisting with maintaining functional stability.

Quick Fact: Pruritus (Itching) and Erythema (Redness) are symptoms for which management is sought.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Econazole Nitrate?

The official eligibility for using Econazole Nitrate is strictly defined by governmental regulatory documents, focusing on populations for whom use is either permitted, restricted, or absolutely contraindicated.


Contraindications and Restrictions

Use of this medicine is contraindicated for individuals with a known hypersensitivity or allergy to econazole nitrate, other imidazole antifungals, or any of the product's inactive ingredients. This restriction is absolute across all formulations.

Age-Based Limitations

While approved for use in adults, the safety and effectiveness of formulations such as the topical foam have not been established in children younger than 12 years of age. Furthermore, vaginal products are generally not indicated for females under 16 years of age. Older adult use is generally permitted, as clinical experience has not identified differences in response.

Pregnancy and Lactation

Use during the first trimester of pregnancy should be avoided. During the second and third trimesters, use is permitted only if clearly needed. As it is not known if the drug is excreted in human milk, caution must be exercised when administered to a nursing woman.

Conditional Use

For vaginal formulations, contact with latex contraceptive devices (e.g., condoms, diaphragms) must be avoided, as excipients may cause damage to the latex material.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Oral anticoagulants (Coumarin derivatives); Local barrier and spermicidal contraceptives.
Specific interacting medicines (if explicitly listed) Warfarin, Acenocoumarol.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction leading to enhanced therapeutic effect of the object drug; Functional/Physical interaction (with contraceptives).
Timing-based interaction rules (if applicable) None explicitly documented as mandatory separation times.
Population-specific interaction notes (if applicable) Interaction with oral anticoagulants is noted to be more likely under conditions that increase systemic absorption, such as application to a large body surface area, use in the genital area, or under occlusion (bandaging).
Interaction-related restrictions Must not be co-administered with latex products (condoms, diaphragms) or spermicidal contraceptives when using the vaginal dosage form.

Resulting interaction structure

Official interaction statements:

  • Concomitant administration with the oral anticoagulant warfarin may result in the enhancement of the anticoagulation effect, necessitating frequent monitoring of the patient's anticoagulation status, including INR/prothrombin time [FDA Prescribing Information].
  • The topical or vaginal product may enhance the effect of acenocoumarol and other coumarin derivatives, which also mandates increased monitoring of the anticoagulant effect [European SmPC].
  • The vaginal dosage form has a documented restriction on use with latex products and spermicidal contraceptives, as components of the product may compromise their functional integrity [European SmPC].

Connection to the overall interaction profile (2–4 sentences): The regulatory documents establish the interaction structure for Econazole nitrate as limited to a pharmacokinetic interaction with oral anticoagulants and a functional restriction involving local contraceptive barriers. This profile reflects the medicine's topical or local route of administration, leading to mandated coagulation monitoring in specific systemic cases and explicit restrictions on local co-administration with barrier contraceptives.

Advertisements

Mechanism of Action

Targeted Inhibition of Fungal Ergosterol Production

The primary mechanism involves the molecule acting as a selective inhibitor of the fungal enzyme lanosterol 14alpha-demethylase (CYP51). This enzyme is essential for the ergosterol biosynthesis pathway—a metabolic process utilized by fungi to synthesize their cell membrane stabilizing sterol. By blocking this pathway, the mechanism triggers both a critical depletion of ergosterol and a damaging accumulation of toxic 14alpha-methylated sterol intermediates. This molecular cascade ultimately leads to profound structural disruption and increased permeability of the fungal cell membrane, resulting in the loss of fungal cell viability or replication capacity.

Secondary Modulation of Host Tissue Inflammation

Beyond its effect on the fungal pathogen, the drug also engages a distinct secondary mechanism by modulating host inflammatory pathways. Specifically, it can reduce the local synthesis of key lipid mediators, such as prostaglandins and leukotrienes. This separate physiological action modulates the host inflammatory pathways, leading to a reduction in the concentration of local inflammatory mediators.

Biological Limitations and Resistance Mechanisms

The effectiveness of the primary fungicidal mechanism is subject to specific biological constraints, notably the emergence of fungal resistance. This occurs when the fungal cell develops counter-mechanisms, such as acquiring mutations in the CYP51 target gene or increasing the activity of drug efflux pumps that actively transport the molecule out of the cell. These adaptations physiologically constrain the drug's ability to reach or bind its target, reducing the functional intensity of the membrane-disrupting cascade.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Econazole Nitrate

The usage of Эконазола нитрат (Econazole nitrate) is limited strictly to local administration, utilizing approved routes that include topical (cutaneous) and intravaginal application. The specific dosage form and the site of application determine the required frequency and duration of treatment.


Dosage and Frequency

Application Type Standard Dosing Regimen Frequency and Duration
Topical Cream (Cutaneous Candidiasis) Apply a sufficient amount to cover affected areas. Twice daily (morning and evening) for 2 weeks.
Topical Cream (Tinea Infections) Apply a sufficient amount to cover affected areas. Once daily for 2 to 4 weeks (4 weeks for tinea pedis).
Topical Foam (Tinea Pedis) Apply to cover affected areas (Ages 12+). Once daily for 4 weeks.
Vaginal Ovules Regimens typically include a 150 mg ovule. Once daily at bedtime for 3 consecutive days.

Procedural and Age-Group Instructions

All formulations are for local use only and must not be used orally, ophthalmically, or intramuscularly.

  • Topical Foam Handling: Due to flammability, the topical foam should be kept away from heat, flame, and smoking during and immediately following application.
  • Intravaginal Precautions: Vaginal formulations should not be used in conjunction with barrier contraceptives made of rubber (e.g., condoms or diaphragms) as the formulation may compromise their integrity.
  • Missed Dose: If an application is missed, it should be applied as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped to avoid double application.
  • Pediatric Use: For topical foam used to treat interdigital tinea pedis, the official regimen is once daily for 4 weeks for patients 12 years of age and older.

These instructions define the standardized, fixed-duration protocol required to complete the treatment course.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Эконазола нитрат

Evidence for Use in Dermatophyte Infections (Ringworm, Athlete's Foot, and Jock Itch)

Research has primarily examined Эконазола нитрат through multi-center, randomized controlled trials (RCTs). These studies were set up to explore how the compound was observed against an inactive substance, often referred to as a vehicle, over defined time intervals. Researchers examined if the application was evaluated for achieving the Complete Cure endpoint, which required monitoring both the visible absence of symptoms—like redness and itching—and confirmation of the fungus being cleared, typically through laboratory tests. Studies reported measurements of microbiological clearance that were observed during the study period.


Evidence for Use in Cutaneous Candidiasis and Tinea Versicolor

Evidence for the use of Эконазола нитрат in treating yeast-related conditions was evaluated in clinical settings. Data show patterns related to how symptoms evolved in the observed populations, with studies monitoring changes in skin presentation over defined time intervals. Systematic reviews, which often combine findings from several individual trials, reported patterns related to measured mycological clearance across the treated populations. Detailed head-to-head comparative evidence is lacking against the newest non-azole topical antifungals.


Long-Term Research and Durability of Response

Clinical trials typically follow participants for a defined period after treatment concludes to establish if the measured outcomes are sustained. This follow-up duration is usually assessed approximately two weeks after the final application of the compound, defining an intermediate-term observation window. Research describing the sustained observation of outcomes over many months or years is not fully established by the existing core trials.


Evidence in Specific Study Populations

Research has explored the use of Эконазола нитрат in specific age groups, including adolescents aged 12 to 17 years. Data for the youngest pediatric populations (children under 12 years of age) remain insufficient in the key regulatory studies for some topical formulations. Furthermore, certain groups, such as patients who are immunocompromised or have uncontrolled diabetes, were typically excluded from the major efficacy trials, meaning subgroup findings are uncertain.


Research Gaps and Areas of Uncertainty

Limited information for long-term outcomes is a key limitation, as the established follow-up durations were short, providing limited insight into post-treatment patterns over extended periods. The research does not determine whether an individual will respond similarly, and certain groups were not included in the main studies, meaning that the findings describe group patterns, not personal outcomes.

Key Studies & References National Institute for Health and Care Excellence (NICE) Clinical Guideline: Dermatophytosis (Tinea) - Summary of Evidence

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Эконазола нитрат (FAQ)


Q: Is Econazole Nitrate the same thing as Econazole?

Econazole Nitrate is the stable salt form of the active medicinal substance, Econazole. Official documents indicate that Econazole Nitrate is the salt, which is typically used in the final drug product, while Econazole is the core antifungal compound belonging to the imidazole family.


Q: How many days or weeks does a typical course of treatment with Econazole Nitrate usually last?

The length of treatment is dependent on the type of infection being treated and the formulation used. The duration is set by the prescribing information and typically falls within ranges, such as 3 days for certain vaginal forms, or up to 2 to 4 weeks for different cutaneous infections, including tinea pedis (athlete's foot).


Q: Is it possible to experience a burning sensation or itching after applying Econazole Nitrate?

Yes, official safety information lists both pruritus (itching) and a skin burning sensation as frequently occurring (Common) adverse reactions. These reactions are typically localized to the area of application, as documented in clinical trials.


Q: Can pregnant individuals use Econazole Nitrate?

Use during the first trimester of pregnancy should be avoided. Official documents indicate that during the second and third trimesters, use is generally permitted only if a clear need exists, based on the assessment that potential benefits justify the potential risks.


Q: Are there any age restrictions for the use of Econazole Nitrate in children?

Yes, official labeling includes age restrictions. For certain forms, such as the topical foam, safety and effectiveness have not been established for children younger than 12 years of age. Vaginal formulations are also generally not indicated for females under 16 years of age.


Q: Is Econazole Nitrate passed into breast milk?

Official documentation states that it is not known whether the medicine is excreted into human breast milk. Regulatory documents further indicate that caution should be exercised when the product is used by a nursing woman.


Q: Can Econazole Nitrate and Warfarin be used together?

Concomitant use with oral anticoagulants, such as Warfarin, may result in an enhancement of the anticoagulation effect. Due to this documented pharmacokinetic interaction, regulatory documents mandate frequent monitoring of the patient's blood clotting status, typically using the INR or prothrombin time.


Q: Can Econazole Nitrate be used on mucous membranes?

Yes, the product is approved for intravaginal administration (internal use in the vagina), which involves application to the mucous membrane. Other formulations are designed specifically for topical application on the skin (cutaneous use).


Q: Why does the medicine contain 'nitrate' specifically?

Econazole Nitrate is a salt (a nitrate salt) of the active ingredient, Econazole. The nitrate salt form is utilized because it is chemically more stable and better suited for use in pharmaceutical formulations than the pure active substance alone, according to official descriptions.


Q: Can Econazole Nitrate cause skin dryness or flaking?

Official side effect listings include terms such as contact dermatitis and application site irritation. These official reactions may be associated with symptoms reported by users, such as skin dryness or flaking.


Q: Can Econazole Nitrate be used for different types of fungus?

Yes, the product is officially indicated for the treatment of a broad range of fungal infections. These include infections caused by dermatophytes (which cause ringworm, athlete's foot, etc.), cutaneous candidiasis (yeast infections), and tinea versicolor.


Q: How soon is the effect of Econazole Nitrate typically noticeable?

Official documents on dosage and administration indicate that most patients experience early symptomatic relief after starting treatment. Clinical improvement, or visible healing, may be noticeable shortly after beginning the treatment duration outlined in the labeling.


Q: If side effects are mild, what is the importance of continuing the full treatment course?

Official recommendations emphasize the necessity of completing the full course of treatment as defined by the label, even if symptoms improve quickly. This is essential to achieve full mycological clearance and reduce the likelihood of the infection recurring.


Q: Are there any specific foods or drinks that should be avoided during treatment?

Official drug interaction documentation does not mention any specific foods or beverages that must be avoided during treatment. This aligns with the medicine's topical route of administration and low systemic absorption.


Q: Can Econazole Nitrate be applied to large areas of skin?

Official information indicates that application to large surface areas of the body or under occlusion (bandaging) may increase systemic absorption. This is important to note as increased absorption raises the potential for systemic drug interactions.


Q: How can an allergy to Econazole Nitrate be distinguished from a common side effect?

Rare but serious reactions, such as hypersensitivity and angioedema (swelling beneath the skin), are distinguished from common reactions (like local itching or burning) because they represent immune system disorders. These more severe reactions are generally described as conditions that necessitate prompt professional assessment.


Q: Are there any data indicating that the fungus can become resistant to Econazole Nitrate?

Yes, the description of the drug's mechanism of action mentions biological limitations, including the possibility of fungal resistance. Resistance can develop through mutations in the fungal target gene or by the fungus increasing the activity of drug efflux pumps.


Q: Should Econazole Nitrate be applied before or after showering?

While specific timing is not mandated, official proper use guidelines for treating conditions like athlete's foot recommend thoroughly drying the skin (especially between the toes) after bathing. This practice suggests that application should occur on clean, dry skin.


Q: Why do doctors sometimes prescribe Econazole Nitrate?

The medicine is prescribed because it is classified as an azole antifungal agent. Its core function, as supported by regulatory and pharmacological data, is to effectively stop the growth and destroy sensitive fungal infections by disrupting their cell membranes.


Q: Which type of fungal infection is most frequently mentioned in studies of Econazole Nitrate?

The research overviews primarily focus on dermatophyte infections (ringworm, athlete's foot, jock itch). These infections are frequently cited as the key target conditions in the multi-center randomized controlled trials used to assess treatment outcomes.


Q: How can one tell that treatment with Econazole Nitrate is helping?

According to the official instructions, signs of positive progress include early relief of symptoms and observable clinical improvement in the appearance of the affected skin. Clinical trials often use symptom resolution and visible healing as key indicators of success.


Q: What happens if a small amount of the cream is accidentally swallowed?

The product is not intended for oral use. Safety documentation indicates the product is harmful if swallowed. In the event of accidental ingestion, the documentation advises contacting a poison control center or healthcare provider if the individual feels unwell.


Q: Is Econazole Nitrate available by prescription or over the counter?

In some official documents, the product is labeled as 'Rx Only' (Prescription Only), particularly for certain concentrations or formulations. However, the dispensing status may vary based on the specific concentration, dosage form, and local regulatory jurisdiction.


Q: Can Econazole Nitrate be used if there are open wounds on the skin?

Official documentation does not provide specific instructions regarding application to open wounds. However, warnings advise that contact with the eyes, nose, or mouth should be avoided, as the product is not intended for internal use.


Q: What are the main conclusions contained in the efficacy studies of Econazole Nitrate?

Clinical studies generally concluded that the medication achieved satisfactory rates of mycological clearance (fungus removal) and the complete cure endpoint when compared against an inactive substance (vehicle) in the tested patient populations.


Q: What conditions other than mycoses (fungal infections) might Econazole Nitrate be used for?

The product is officially indicated for the treatment of fungal infections caused by dermatophytes and yeasts. While the mechanism of action also involves a secondary modulation of host inflammation, this is not listed as a standalone approved indication for the medicine.


Q: Can one drive a car or operate machinery while using Econazole Nitrate?

Because the systemic absorption of the topical cream is very low, official documentation does not mention any known effects of the medication on the user's ability to drive vehicles or operate heavy machinery.


Q: What precautions are described in the official documents?

Official precautions include strictly avoiding contact with the eyes. The vaginal formulations have a specific restriction against co-administration with latex barrier contraceptives. Additionally, flammable foam formulations must be kept away from heat, flame, and smoking.


Q: What are the alternative names (brand names) for Econazole Nitrate?

The product may be sold under various trade names depending on the manufacturer and region, such as Spectazole, Ecostatin, or Pevaryl. Official drug information resources often list these common brand names in the product description.


Q: Why is it important to maintain hygiene when using Econazole Nitrate?

Proper use guidelines, such as thoroughly drying the affected area and frequently changing clothing or footwear, are recommended. This is intended to support the treatment process and may help reduce the likelihood of recurrence.


Q: Is there any information about Econazole Nitrate overdose?

Due to the low systemic absorption when used topically, overdose is considered unlikely. However, safety documents related to accidental oral ingestion indicate that a call to a doctor or poison control center may be warranted if the individual feels unwell.


Q: How long does Econazole Nitrate stay in the body after stopping use?

The systemic absorption after topical application is minimal. Clinical pharmacology data indicate that less than 1% of the applied dose is typically excreted via the urine and feces, showing a minimal and short-lived presence in the body after the treatment is stopped.


Q: What are the main clinical trials for Econazole Nitrate?

The main trials used for regulatory approval are multi-center randomized controlled trials (RCTs). These studies were structured to compare the drug's performance against an inactive vehicle to determine its effectiveness in achieving the defined clinical endpoints.


Q: What are the general expectations for full recovery after a course of treatment?

Studies indicate that both mycological clearance and clinical cure are generally observed within the standard 2- to 4-week treatment window. However, long-term follow-up data after treatment is often limited to intermediate periods, usually about two weeks after the final application.

Advertisements

How should Эконазола нитрат be stored and disposed of?

Storage and Disposal Requirements for Econazole Nitrate

Storage Conditions

Econazole Nitrate cream must be stored at controlled room temperature, specifically below 86 F (30 C). The topical foam formulation requires special handling as it is a pressurized container containing flammable material. Do not store the foam at temperatures above 120 F (49 C), and the container must not be punctured or incinerated.

All formulations must be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired Econazole Nitrate product must be disposed of through an approved waste disposal plant or an appropriate treatment facility. Disposal must be conducted in accordance with local/regional regulations for pharmaceutical waste and must not be placed in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Эконазола нитрат found in:

A-Z Index: